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Abstract
Background: A substantial number of individuals are at risk for the development of motion sickness induced nausea and
vomiting (N&V) during road, air or sea travel. Motion sickness can be extremely stressful but the neurobiologic mechanisms
leading to motion sickness are not clear. The endocannabinoid system (ECS) represents an important neuromodulator of
stress and N&V. Inhibitory effects of the ECS on N&V are mediated by endocannabinoid-receptor activation.
Methodology/Principal Findings: We studied the activity of the ECS in human volunteers (n = 21) during parabolic flight
maneuvers (PFs). During PFs, microgravity conditions (,1022 g) are generated for approximately 22 s which results in a
profound kinetic stimulus. Blood endocannabinoids (anandamide and 2-arachidonoylglycerol, 2-AG) were measured from
blood samples taken in-flight before start of the parabolic maneuvers, after 10, 20, and 30 parabolas, in-flight after
termination of PFs and 24 h later. Volunteers who developed acute motion sickness (n = 7) showed significantly higher
stress scores but lower endocannabinoid levels during PFs. After 20 parabolas, blood anandamide levels had dropped
significantly in volunteers with motion sickness (from 0.3960.40 to 0.2260.25 ng/ml) but increased in participants without
the condition (from 0.4360.23 to 0.6060.38 ng/ml) resulting in significantly higher anandamide levels in participants
without motion sickness (p = 0.02). 2-AG levels in individuals with motion sickness were low and almost unchanged
throughout the experiment but showed a robust increase in participants without motion sickness. Cannabinoid-receptor 1
(CB1) but not cannabinoid-receptor 2 (CB2) mRNA expression in leucocytes 4 h after the experiment was significantly lower
in volunteers with motion sickness than in participants without N&V.
Conclusions/Significance: These findings demonstrate that stress and motion sickness in humans are associated with
impaired endocannabinoid activity. Enhancing ECS signaling may represent an alternative therapeutic strategy for motion
sickness in individuals who do not respond to currently available treatments.
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Introduction
Between 7% and 28% of individuals report symptoms of acute
motion sickness during road [1], air [2] or sea travel [3]. Motion
sickness can be extremely debilitating and yet, the present
understanding of the neurobiologic mechanisms leading to motion
sickness is incomplete. The traditional sensory conflict hypothe-
sises including the ‘‘neuronal mismatch theory’’ suggests that
motion sickness results from a conflict between actual and
anticipated signals from sensory organs sub-serving spatial
orientation [4,5]. These theories do not explain individual motion
sickness susceptibility, however, and do not allow individual risk
prediction for motion sickness [6]. More recent studies point to a
genetic predisposition of individuals to motion sickness with a large
inherited susceptibility component [7,8]. Furthermore, motion
induced nausea and vomiting (N&V) is known to be linked to a
pronounced activation of the glucocorticoid- and the symphati-
coadrenergic stress response systems [9]. Acute motion sickness
can be regarded as the result of an intense gut-brain interaction in
a stressful situation. An important regulator of this interaction
under physiologic conditions and under stress is the endocanna-
binoid system (ECS) [10]. The ECS consists of at least two G-
protein-coupled receptors named CB1 and CB2, specific endog-
enous ligands called endocannabinoids (e.g. anandamide and 2-
arachidonoylglycerol) and a number of biosynthetic enzymes and
uptake and degradation systems [11]. The ECS is assumed to
connect the physical and emotional responses to stress with
gastrointestinal function and energy regulation. As such, the ECS
has also been regarded as a general stress recovery system [12].
There is evidence of an important inhibitory CB-receptor
mediated effect of the central and peripheral ECS on N&V in
rodents [13,14,15]. Furthermore, the use of the CB1-receptor
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blocker rimonabant in humans as an anti-obesity drug was
associated with an increased incidence of N&V along with an
impaired stress response [16]. This findings suggest an involve-
ment of endocannabinoid signaling in the regulation of N&V and,
presumably, also of motion sickness and stress. The role of
endocannabinoids in humans with this condition has never been
investigated, however. We studied the activity of the ECS in first-
time participants of a parabolic flight experiment and showed that
the motion sickness during kinetic stimulation was accompanied
by a significantly lower reactivity of the peripheral endocannbi-
noid system.
Methods
Objectives
We studied the activity of the ECS in first-time participants of a
parabolic flight experiment and tested the hypothesis whether
motion sickness stress during kinetic stimulation was accompanied
by changes in reactivity of the peripheral endocannabinoid system.
Participants
Twenty-one healthy male individuals (age: 41.061.5 years;
height: 180.661.6 cm; weight: 79.562.7 kg; body mass index:
24.360.6) participated in the experiments which were performed
during three campaigns between May 2006 and September 2007.
All subjects received full flight medical approval according to JAR-
FCL 3 German version.
Description of the Investigations and Procedures
undertaken
Parabolic Flight. Parabolic flights (PFs) were performed with
an Airbus A300 ZeroG (Novespace, France). During a parabolic
flight maneuver, microgravity conditions (,1022 g) are generated for
approx. 22 seconds. Each parabola is initiated with a 1.8 g pull-up
and terminated with a 1.8 g pull-out by the aircraft. During an
average mission, 30 regular parabolas are flown with 8 min breaks
(periods of horizontal flights) after 10 and 20 maneuvers. All
volunteers received weight-adapted oral scopolamine (0.4–0.6 mg)
1 h before flight and were seated in a regular aircraft seat restrained
by a seat belt. A possible effect of oral scopolamine on blood
endocannabinoids was excluded in a ground based control
experiment in 3 volunteers where endocannabinoids were
measured before scopolamine, after 1 hour and after 3 hours after
drug ingestion. Anandamide and 2-AG blood levels showed no
significant change over time (data not shown).
Endocannabinoid Measurements. Venous blood samples
for endocannabinoid measurements were taken in-flight before
start of the parabolic maneuvers (T0), after 10 (T1), 20 (T2), and
30 (T3) parabolas, in-flight after termination of the parabolic
cycles (T4) and 24 h later (T5). Blood samples were drawn into
EDTA containing tubes (S-MonovetteH, Sarstedt, Numbrecht,
Germany), immediately frozen on dry ice and then kept at280uC.
When stored under these conditions, endocannabinoids are stable
for up to 6 months [17]. The time interval between blood
sampling and freezing was minimized because previous
experiments have shown that endocannabinoid generation in
native blood samples is continued ex-vivo [18].
Whole blood concentrations of the endocannabinoids anandamide
and 2-arachidonoylglycerol (2-AG) were determined within 6 months
after the experiments using a method based on high performance
liquid chromatography-tandem mass spectrometry (HPLC-MS/MS)
which has previously been described [18]. Our method is linear at
least within a range of 0.1 to 2 ng/ml for anandamide and 0.5 to
10 ng/ml for 2-AG. The inter-assay coefficient of variation is 34% for
a mean anandamide concentration of 0.2 ng/ml. The lower limit of
detection of the method (defined as a signal/noise ration .4:1) is
0.025 ng/ml for anandamide and 0.33 ng/ml for 2-AG. In biological
matrices, 2-AG (including its deuterated analog) rapidly isomerizes to
1-AG [19]. We therefore quantified 2-AG as the sum of 1- and 2-
esters of arachidonic acid.
Gene expression analyses of endocannabinoid receptors.
Gene expression analysis of CB1 and CB2 receptors was performed
in leucocytes isolated from blood samples (9 ml) drawn 24 h before
and 4 h after the flight experiment using the LeukoLOCKTM Total
RNA Isolation Kit as per manufacturer’s instructions (Applied
Biosystems Foster City, CA, USA). All 7 individuals who developed
motion sickness were selected for gene expression analyses. Another
7 age and body weight matched participants without motion sickness
served as controls. Quantity and quality of RNA was determined
using a spectrophotometer; quality of the RNA revealed satisfactory
in all cases (260/280 nm absorbance ratio between 1.95 and 2.15).
Hereafter, equal amounts from the different samples of amplified
RNA (1000 ng) were transcribed into cDNA. The reverse
transcripton (RT) reaction was carried out using mixed oligo-dT
and random primers and Superscript III reverse transcriptase
(Invitrogen, Carlsbad, USA) following the manufacturer’s protocol.
Quantity and quality of the RNA was determined using a
spectrophotometer; quality of the RNA was satisfactory in all cases
(260/280 nm absorbance ratio between 1.95 and 2.15). Equal
amounts of the different samples of RNA (1000 ng) were transcribed
into cDNA. The RT reaction was carried out using mixed oligo-dT
and random primers and Superscript III reverse transcriptase
(Invitrogen, Carlsbad, USA), as per manufacturer’s instructions.
Real-time qPCR was performed in triplicates with the Light
Cycler 480 instrument (Roche Diagnostics, Mannheim, Ger-
many). For cannabinoid receptor quantification Roche’s qPCR
Mastermix and highly specific fluorogenic primer-probe sets
synthesized by Primerdesign, Southampton, United Kingdom,
were used as previously described [20].
Glucocorticoid measurements. Salivary samples for
cortisol measurements were obtained using SalivetteH sampling
devices (Sarstedt, Germany) simultaneously with blood sampling
for endocannabinoid measurements at T0-T5. Free cortisol in
saliva was quantified by an automated immunoassay system based
on the principle of electrochemiluminescence (Elecsys Cortisol,
Roche Diagnostics, Mannheim, Germany).
Quantification of Stress and N&V. At each time point (T0-
T5), subjects completed the German Kurzfragebogen zur aktuellen
Beanspruchung (short questionnaire of current stress; KAB [21]). The
questionnaire is highly sensitive to short-term or situational
changes in subjective stress experience. It is composed of 6 items
of paired positive and negative adjectives, referring to perceptions
of current stress and strain or relaxation (e.g. ‘‘tense–calm’’,
‘‘uneasy–relaxed’’). Subjects give their ratings on a six-point scale.
The range for total item means is 1–6, with higher values
indicating an increased stress experience. Because of the
composition of the questionnaire, it is usually not possible to
remember the previous ratings, thus preventing carryover effects.
Nausea scores were assessed on a verbal rating scale ranging
from 1= no nausea to 6 = maximal nausea at each time point. In
order to document the occurrence of active vomiting, all
experiments were video taped while in-flight (time points T0-T4)
and analyzed offline.
Ethical considerations
The study was approved by the Ethical Committee of the
University of Munich (Protocol#152-06). All participants signed
Endocannabinoids & Kinetosis
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informed consent and received flight medical approval according
to JAR-FCL 3 German version.
Statistical methods
All variables were tested for normal distribution using the
Kolmogorov-Smirnov test. Blood endocannabinoid and saliva
cortisol concentrations at the 6 time points of measurement
between volunteers with and without motion sickness were
compared using a Repeated Measure General Linear Model
(RM-ANOVA) with time point of measurement as a within subject
effect and the occurrence of motion sickness as a between subject
effect. When RM-ANOVA showed a significant effect, a t-test in
normally distributed data or a Mann-Whitney U test in case of
non-parametric data was used to determine at which time point
endocannabinoid blood and saliva cortisol levels were significantly
different. CB – receptor expression 24 h before and 4 h after the
experiment was compared by paired t-test or by the Wilcoxon
Signed Rank Test in case of nonparametric data. The Pearson
correlation coefficient was calculated as a measure of linear
association between parametric variables, Spearman’s rho was
used for non-normally distributed data. A p-value ,0.05 was
regarded as statistically significant. Data are presented as
mean6SD with exception of figures, where mean6SEM is used
to increase clarity. Statistical calculations were performed using
PASW Statistics 17.0 and Sigma Plot 11.0, Chicago, Illinois, USA.
Results
Parabolic flight resulted in an acute stress reaction and
motion sickness in one third of the participants
From 21 volunteers, 7 developed acute motion sickness
associated N&V. From time point T1 (after 10 parabolas) to the
in-flight post-parabola phase of the experiment (T4), these
individuals showed significantly higher KAB stress symptom
scores. Nausea scores in participants with acute motion sickness
increased later than stress scores and were significantly higher
between the time points T2 and T4 (Table 1).
There were no significant differences regarding demographic
variables between individuals who developed motion sickness and
those who did not (Table 2).
Acute motion sickness was associated with significantly
lower blood endocannabinoid levels
Volunteers with acute motion sickness showed significantly
lower endocannabinoid blood concentrations during the exposure
to kinetic stress. RM-ANOVA demonstrated a significant between
group effect of motion sickness for anandamide (Type III Sum of
Squares = 0.95, F = 4.7, p = 0.04) and for 2-AG (Type III Sum of
Squares = 628.1, F = 8.4, p = 0.01).
After 10 parabolic maneuvers (T1), anandamide blood levels
dropped in individuals with motion sickness but increased in
volunteers without. After termination of parabolic cycling (T4),
anandamide concentrations returned to baseline in both groups
(Figure 1, Panel A). Blood concentrations of the endocannabinoid 2-
AG in volunteers with motion sickness remained almost non-reactive
throughout the experiment but increased continuously in individuals
without motion intolerance. After termination of the parabolic
maneuvers but still in flight (T4), 2-AG blood concentrations in
participants who tolerated the experiment without developing motion
sickness reached maximal values and were significantly higher than in
volunteers with motion intolerance (Figure 1, Panel B).
Nausea scores correlated negatively with anandamide blood
levels after 30 parabolas (T3, r =20.61, p = 0.02) but not at other
time points or with 2-AG concentrations. KAB stress symptom
scores at T3 were negatively related to blood anandamide
concentrations (r =20.47, p = 0.04) and to 2-AG levels
(r =20.64, p,0.01) but did not correlate with endocannabinoid
levels at other time points.
Endocannabinoid receptor expression declined in
volunteers with motion sickness
Gene expression analysis was performed in leucocytes isolated 24 h
before and 4 h after the parabolic flight experiment in all 7
individuals with motion sickness and in 7 matched volunteers without
motion intolerance. As compared to baseline values before flight,
CB1 – receptor expression at 4 h after exposure to kinetic stress
Table 1. Stress and nausea during the experiment.
Score
In-flight pre-
parabolas (T0)
After 10
parabolas (T1)
After 20
parabolas (T2)
After 30
parabolas (T3)
In-flight post -
parabolas (T4)
24 h after
parabolas (T5)
Motion Sickness Motion Sickness Motion Sickness Motion Sickness Motion Sickness Motion Sickness
yes no yes no yes no yes no yes no yes no
KAB – Stressa 2.461.2 2.360.9 3.461.4* 2.160.7 4.161.3* 1.960.6 3.761.2* 1.560.5 2.861.1* 1.760.7 1.560.6 1.760.5
Nauseab 1.060.0 1.060.0 1.160.4 1.060.0 1.960.7# 1.060.0 4.361.7# 1.060.0 2.761.8# 1.060.0 1.060.0 1.060.0
Comparison of KAB stress symptom and nausea scores between participants with and without motion sickness during the parabolic flight experiment.
*p,0.01 and
#p,0.005 when compared to participants without motion sickness. Data are mean6SD.
aGerman Kurzfragebogen zur aktuellen Beanspruchung (short questionnaire of current stress; KAB) [21].
bNausea was quantified on a verbal rating scale ranging from 1= no nausea to 6 = maximal nausea.
doi:10.1371/journal.pone.0010752.t001
Table 2. Demographic data.
No motion
sickness (n =14)
Motion
sickness (n =7)
Age (y) 42.366.5 38.266.6
Size (m) 1.7960.71 1.8660.60
Weight (kg) 79.8611.9 79.5612.1
Body Mass Index 24.862.6 23.062.0
Demographic data of participants with and without motion sickness during the
experiment. There were no significant differences between individuals who
developed kinetosis and those who did not (p.0.11).
doi:10.1371/journal.pone.0010752.t002
Endocannabinoids & Kinetosis
PLoS ONE | www.plosone.org 3 May 2010 | Volume 5 | Issue 5 | e10752
declined significantly in volunteers who developed acute motion
sickness but remained unchanged in participants who did not. No
change over time was seen in CB2 - receptor expression (Figure 2).
There was no significant difference in relative CB receptor expression
at baseline 24 h before the experiment between volunteers with or
without motion intolerance (CB1: 0.41 vs. 0.48, median values,
p=0.46; CB2: 1.24 vs. 1.14, p=0.65).
Low endocannabinoid blood concentrations were
accompanied by massive activation of the HPA – axis
Volunteers with a low-reactive ECS and acute motion sickness
showed a pronounced increase in saliva cortisol whereas cortisol
values in individuals without motion intolerance remained nearly
unchanged throughout the experiment (RM-ANOVA for the
between group effect: Type III Sum of Squares = 2.4, F = 4.6,
p = 0.04). At the end of parabolic cycling (T4), cortisol concen-
trations in individuals with motion sickness were significantly
higher than in motion tolerant participants (Figure 3) and were
negatively related to anandamide blood levels after 30 parabolas in
the complete sample (T3, r =20.57, p = 0.03, n= 21). Saliva
cortisol concentrations correlated negatively with CB1 mRNA
expression 4 h after the experiment (r =20.71, p= 0.03, n= 14)
but not with CB2 receptor mRNA (r = 0.03, p = 0.96, n= 13).
Positive relationships were seen between saliva cortisol at T4 and
Figure 1. Whole blood endocannabinoid concentrations during a parabolic flight experiment in 21 male volunteers. Panel A
compares blood concentrations of the endocannabinoid anandamide between volunteers who developed motion sickness accompanied by severe
N&V (n = 7, red lines) and those who did not (n = 14, blue lines). After the 10th parabolic maneuver (T1), anandamide blood concentrations dropped in
individuals with motion sickness but increased in volunteers without (Mann-Whitney U Statistic = 14.5, T = 42.5, *p = 0.02). After the 20th maneuver
(T2), this difference remained significant (Mann-Whitney U Statistic = 14.0, T = 42.0, *p = 0.01). Panel B shows the same comparison with regard to the
endocannabinoid 2-AG. 2-AG values in volunteers with motion sickness remained almost constant and non-reactive but increased in individuals
without. *indicates significantly higher 2-AG blood concentrations in individuals without motion sickness after termination of parabolic maneuvers
(Mann-Whitney U Statistic = 0.0, T = 85.0, p = 0.04).
doi:10.1371/journal.pone.0010752.g001
Endocannabinoids & Kinetosis
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KAB stress scores (r = 0.83, p,0.01, n= 21) as well as nausea
intensity (r = 0.72, p,0.01, n = 21).
Discussion
The results of this study point to the fact that the ECS is involved in
the neurobiologic mechanism of motion sickness. Previous studies
have already suggested that the ECS has an important role in the
pathophysiology of N&V induced by diseases (e.g. migraine) [22] and
many drugs (e.g. cancer chemotherapy) [13,23]. In animal
experiments, cisplatin induced emesis could be blocked by cannabi-
noid agonists [14]. This anti-emetic effect of cannabinoids involves
both central and peripheral mechanisms [24] and is mediated by
both CB1- [14] and CB2-receptors [25,26]. Emesis and emetic
afferences from the gut are controlled by the dorsal vagal complex of
the brainstem which consists of the area postrema, the nucleus tractus
solitarius and the dorsal motor nucleus of the vagus. There is strong
evidence supporting the presence of CB1- and CB2-receptors in these
brain areas mediating anti-emetic responses [15,26,27]. Although
measured peripherally, individuals from our study with acute motion
sickness showed both, reduced blood endocannabinoid levels and a
downregulation of CB1-receptor expression. A peripheral site of
action of endocannabinoids at the terminals of vagal afferents in the
gastrointestinal tract has recently been demonstrated where en-
docannabinoids are involved in the complex regulation of food intake
[28] as well as in a downregulation of toxin induced emesis [29].
Our finding of differences in CB1-receptor expression between
individuals with and without motion sickness is more difficult to
explain, however. While blood endocannabinoid levels could reflect
to some extent a spill-over of endocannabinoids from peripheral
tissues involved in N&V as well as cortisol release [30], this does not
apply to CB1-receptors which were measured on blood cells. Blood
cells themselves are, however, a significant source of endocannabi-
noids [18] and this, together with the CB1-receptor expression
measured on these cells indicates differences in stress-induced
activation of the ECS in blood cells between individuals with and
without motion sickness. An activation of the peripheral ECS by
physical [31] and emotional stress [32] has recently been
demonstrated. Within this context it is of interest to note that
volunteers who later developed motion sickness had, albeit not
significantly, lower endocannabinoid blood levels in-flight during the
pre-parabola phase of the experiment when kinetic stimulation was
low but stress exposure may have been already high. This suggests
differences in the endocannabinoid response to stress between
individuals prone to develop motion sickness and those who are not.
The observation that lower endocannabinoid levels in participants
with motion sickness were accompanied by a lower expression of
CB1-receptors may appear counterintuitive but could point to a
failure of upregulation in endocannabinoid signaling during stress
exposure. There is also preliminary evidence that alterations of the
ECS in blood cells mirrors dysfunctions of central endocannabinoid
signaling and that peripheral blood may serve as a reservoir of
anandamide for the brain [33]. Thus, lower peripheral endocanna-
binoid activity in individuals with motion sickness may indicate
central ECS dysfunction which could help to explain many central
symptoms of motion sickness including N&V [34].
Another interesting observation from our study is that
anandamide and 2-AG seem to play different roles in the
adaptation to parabolic flight stress and motion sickness. Changes
in anandamide blood levels are seen earlier and seem more
associated with nausea and the stress reaction during the parabolic
maneuvers, whereas changes in 2-AG blood levels appear later
and seem more closely related to stress recovery immediately after
the parabolas. 2-AG is known to be more selective for CB1
receptors which play an important role in stress recovery reactions
[35].
Participants with acute motion sickness did not only show low
endocannabinoid signaling, they also demonstrated a massive
activation of the hypothalamic-pituitary-adrenal (HPA) axis. Al-
though one could assume that HPA-axis activation under the
conditions of acute motion sickness is simply a non-specific reaction to
stress, there is increasing evidence that endocannabinoids provide a
tonic and highly specific feedback to control HPA-axis activity [36].
These effects may occur both at a peripheral [37] as well as on a
central level where it has been shown that the ECS is a negative
regulator of the HPA-axis and that the levels of 2-AG (but not
anandamide) in the hypothalamus regulate the corticosterone
response to stress [10]. In particular, high levels of 2-AG dampen
HPA-axis activity whereas a stress associated decline in 2-AG levels
reduced activation of CB1-receptors resulting in increased HPA-axis
activity [38]. These findings from animal experiments remarkably
resemble our observations in humans and give further evidence that a
failure to up-regulate and to maintain endocannabinoid signaling
during kinetic stimulation may result in both, an increased risk for the
development of motion sickness with N&V and a pronounced stress
response. An impairment in endocannabinoid signaling may
therefore be an important link between stress responsiveness and
the development of motion sickness and could represent a
neurobiologic mechanism leading to this common disorder. Our
findings also suggest that pharmacologic enhancement of endocan-
nabinoid signaling may represent an alternative prophylactic or
therapeutic approach for motion sickness in patients who do not
respond to currently available treatments [13,39].
Limitations
This study investigated only a limited number of subjects and a
larger sample size would have been preferable. However, due to the
Figure 2. Comparison of leukocyte cannabinoid receptor mRNA
between volunteers with andwithoutmotion sickness during the
parabolic flight experiment. RNA was prepared from whole blood and
subjected to quantitative RT-PCR (triplicate determinations). Data were
calculated relative to GAPDH and RPL13A-mRNA using an efficiency-
corrected algorithm. *indicates a significant decline in CB1-receptor mRNA
(W=226.0, T+=1.0, T- =227.0, p=0.03, Wilcoxon Signed Rank Test) in
volunteers with motion sickness when compared to 24 h pre-flight values.
CB1-receptor mRNA in individuals without motion sickness remained
unchanged over time (W=28.0, T+=10.0, T- =218.0, p=0.58) as was
CB2-receptor expression before and after the experiment. Horizontal black
bars in the boxplots indicate median values; upper and lower lines of the
boxes show the 5th and 95th percentile.
doi:10.1371/journal.pone.0010752.g002
Endocannabinoids & Kinetosis
PLoS ONE | www.plosone.org 5 May 2010 | Volume 5 | Issue 5 | e10752
severity of the model the limited sample size appears to be less critical
as the subjects’ stress responses with or without motion sickness were
clearly distinguishable. Other limitations include possible effects of
the antiemetic drug scopolamine on our findings. Although all
participants received the compound and the drug did not affect
endocannabinoid blood levels directly, this does not rule out that
muscarinic receptor blockade could influence the sensitivity of CB-
receptors. Interactions between muscarinic receptors and endocan-
nabinoid signaling have been observed in the hippocampus, a brain
area critical for spatial orientation [40]. Although such an interaction
cannot be ruled out completely, the effect should at least be the same
in both groups. Performing the experiment without anti-emetic
medication would be difficult to justify.
Our study did not address the question if lower endocannabi-
noid blood levels in individuals with motion sickness were due to
baseline differences in the expression of enzymes involved in
endocannabinoid biosynthesising or degradation [41]. If no such
difference exists, this would suggest variations in transcriptional
control events over endocannabinoid signaling. These important
questions will have to be addressed in further studies.
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